Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Randomized Controlled Trials May Be Less Burdensome, FDA Guidance Says

This article was originally published in The Gray Sheet

Executive Summary

Randomized controlled clinical trials of medical devices represent, in certain circumstances, the least burdensome route for sponsors to gain FDA approval, the agency maintains.

You may also be interested in...



LBITF, FDA "Concept and Principles" Draft Attests Collaborative Effort

Reviewers of 510(k) premarket submissions should limit their analyses to claims "that present a major impact on the intended use of the device," according to principles set forth in a least burdensome industry task force (LBITF) and FDA draft document released for comment on FDA's website March 20.

LBITF, FDA "Concept and Principles" Draft Attests Collaborative Effort

Reviewers of 510(k) premarket submissions should limit their analyses to claims "that present a major impact on the intended use of the device," according to principles set forth in a least burdensome industry task force (LBITF) and FDA draft document released for comment on FDA's website March 20.

Post-Market Studies May Be "Least Burdensome" Alternative - Industry

FDA should consider postmarket controls for breakthrough devices as an alternative to randomized, controlled clinical studies as a "least burdensome" route to approval, a pan-industry task force suggests in Nov. 24 comments on FDA's draft guidance.

Related Content

UsernamePublicRestriction

Register

MT012274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel